11:33 AM EDT, 09/10/2024 (MT Newswires) -- Roivant Sciences ( ROIV ) said Tuesday its Pulmovant unit presented "positive" data from phase 1b testing of its mosliciguat drug candidate, with the prospective treatment for pulmonary hypertension showing the potential for differentiated efficacy, safety and convenience in patients during a recent proof-of-concept trial.

Mosliciguat also demonstrated a favorable safety profile and is unique among inhaled pulmonary hypertension therapies by requiring only one dose daily compared to multiple doses each day with rival treatments, the company said.

Based on the early-stage results, Pulmovant said it expects to soon begin phase 2 testing of mosliciguat in around 120 adults with pulmonary hypertension associated with interstitial lung disease - a patient group, the company said, with limited treatment options currently in both the US and Europe.

Price: 12.38, Change: -0.13, Percent Change: -1.00